WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the closing of its previously announced public offering, including the exercise in full by the underwriters of their option to purchase an additional 1,072,500 shares of common stock at the public offering price of $7.00 per share. The exercise of the underwriters’ option brought the total number of shares of common stock sold by OvaScience to 8,222,500 shares and increased the total net proceeds raised in this offering to $53.8 million, after deducting underwriting discounts and commissions and estimated expenses. OvaScience intends to use the proceeds from this offering to fund the commercial expansion of the AUGMENTSM treatment in its key regions, Japan and Canada, the ongoing pre-commercial activities for the OvaPrimeSMtreatment and the OvaTureSM treatment, and working capital and other general corporate purposes.
Leerink Partners LLC acted as sole book runner for the offering. Oppenheimer & Co. Inc., H.C. Wainwright & Co., Roth Capital Partners, LLC and JonesTrading Institutional Services LLC acted as co-managers of the offering.
About OvaScience
OvaScience, Inc. (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because it believes women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience has commenced a non-commercial preceptorship training program with the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S.
